Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20248696 | 1.00 | PRMT6 (0.47) | PRMT6P2RY12BMPR1BDNPH1ADORA1 | |
| SCHEMBL13020645 | 0.97 | PRMT6 (0.47) | PRMT6P2RY12BMPR1BDNPH1ADORA1 | |
| SCHEMBL29558159 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL18310600 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL20248698 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL18992232 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL18048070 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL20353074 | 0.95 | PRMT6 (0.48) | PRMT6P2RY12ADORA1 | |
| SCHEMBL20483101 | 0.93 | PRMT6 (0.46) | PRMT6P2RY12ADORA1 | |
| SCHEMBL29814296 | 0.93 | PRMT6 (0.46) | PRMT6P2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | PRMT6 4428/4885P2RY12 203/4885BMPR1B 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.